Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

NOX-E36 (emapticap pegol) binds and neutralizes the human chemokine CCL2* and the related chemokines CCL8, CCL11 and CCL13. CCL2 is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages. Both CCL2 and its receptor CCR2 have been demonstrated to be induced and involved in a variety of inflammatory diseases and are implicated in cancer spread and immune privilege of tumors. One key function of CCL2 is the recruitment of immunosuppressive cell populations of the innate immune system such as Tumor Associated Macrophages (TAMs). Removing TAMs from the tumor microenvironment with NOX-E36 should allow an improved immune response against tumors.

Phase 1 and 2 studies with NOX-E36 have shown its ability to target macrophages in a dose-dependent manner and have established its safety and tolerability profile in over 100 subjects. NOXXON has developed plans for clinical development of NOX-E36 in pancreatic and lung cancer (non-small cell).

*CCL2 (C-C Chemokine Ligand 2) is also referred to as MCP-1 (Monocyte Chemoattractant Protein 1)

Recent clinical studie available at clinicaltrials.gov

  • NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
    (ref: NCT01547897)
    Status: completed

Recent NOX-E36 press releases


NOX-E36 press release archive

NOX-E36 publication archive